Fortress Biotech (FBIO) Stock: Buy, Sell, or Hold?
FBIO - Fortress Biotech, Inc.
$1.90
-0.05 (-2.56%)
▼
5d:
-6.86%
30d:
-23.69%
90d:
-44.44%
WAIT
LOW Confidence
Analysis Updated: Oct 13, 2026 12:00 AM ET
Earnings: Nov 13, 2026
29d
Get Alerted When FBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: FBIO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: FBIO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: FBIO is currently trading at $1.90, which is considered oversold relative to its 30-day fair value range of $2.06 to $2.51. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.9) compared to its historical average (136.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FBIO is in a downtrend. The price is currently testing key support at $1.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FBIO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.00 (+156.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FBIO is in a downtrend. The price is currently testing key support at $1.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FBIO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.00 (+156.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.06 -
$2.51
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 156.4% below Wall St target ($5.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.06 -
$2.51
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.88
Resistance Level
$2.17
Current Trend
Downtrend
Technical data as of
Oct 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.95
Wall Street Target
$5.00
(+156.4%)
Revenue Growth (YoY)
14.0%
Profit Margin
163.3%
PE vs Historical
-2.0 vs 136.2
CHEAP
Share & Embed Analysis
Last updated: October 14, 2026 4:41 PM ET
Data refreshes hourly during market hours. Next update: 5:41 PM
Data refreshes hourly during market hours. Next update: 5:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 62 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$572 | 42 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
29 analysts |
$371 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
20 analysts |
$306 | 57 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 67 BUY |
